Cara Therapeutics Shares Up, Says FDA Approves Korsuva Injection
August 23 2021 - 6:24PM
Dow Jones News
By Stephen Nakrosis
Shares of Cara Therapeutics are trading higher in Monday's
after-hours market, following an announcement by Cara and Vifor
Pharma that the U.S. Food and Drug Administration approved the
Korsuva injection to treat pruritus in hemodialysis patients.
The companies said the Korsuva injection is the first and only
therapy approved by the FDA to treat pruritus associated with
chronic kidney disease in adult patients undergoing
hemodialysis.
At 5:54 p.m. ET, Cara shares were trading 24.65% higher at
$17.80 a share. Volume at the time topped 5.1 million shares.
The company's shares finished the day's regular-trading session
with a 4.23% gain, closing at $14.28 each.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 23, 2021 18:18 ET (22:18 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024
